Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2010 Jan;10(1):1-18. doi: 10.1517/14712590903319656.

Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.

Author information

1
Human Genome Sciences, Rockville, MD 20850, USA.

Abstract

IMPORTANCE OF THE FIELD:

Agents that activate the TNF-related apoptosis-inducing ligand death receptors, TRAIL-R1 and TRAIL-R2, have attracted substantial attention and investment as potential anti-cancer therapies. Preclinical studies of TRAIL-R agonists indicate that they may be efficacious in a wide range of tumor types, especially when combined with chemotherapeutic agents.

AREAS COVERED IN THIS REVIEW:

The rationale for clinical development of TRAIL-R agonists is described, including the basis for combining these agents with other agents that modulate the 'checks and balances' of the apoptotic pathways. Accruing data that highlight differences between TRAIL-R1 and TRAIL-R2 that could affect the clinical significance of their specific agonists are described. The clinical experience to date with each of the agonists is summarized.

WHAT THE READER WILL GAIN:

The reader will gain an understanding of the rationale for the clinical development of TRAIL-R agonists, as well as the current status of clinical trials of these interesting new agents.

TAKE HOME MESSAGE:

Ongoing clinical trials will provide important information regarding the future development of TRAIL-R agonists.

PMID:
19857186
DOI:
10.1517/14712590903319656
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center